HBV associated acute on chronic liver failure
Conditions
Interventions
B:lamivudine
Sponsors
Liver Failure Treatment and Research Center, 302 Military Hospital ,Beijing, China
Eligibility
Sex/Gender
All
Age
16 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) age 16-65, male or female; (2) HBVDNA positive; (3) No antiviral therapy with nucleoside analogues within six months; (4) HBV associated ACLF was diagnosed according to the national clinical guidelines on liver failure (issued in 2006)12, including TBil>170umol/L or daily increase >=17umol/L, and PA from 20% to 40%, with or without hepatic encephalopathy below IIo and ascites.
Exclusion criteria
Exclusion criteria: (1) terminal-stage patients with PA<20%, or with severe complications should be excluded, such as hepatic-renal syndrome, severe infection, massive hemorrhage of the digestive tract, and refractory electrolyte disturbances; (2) Concurrent viral infection should be excluded, including HAV, HCV, HDV, HEV, HIV, CMV, EBV etc.; (3) Liver failure caused by other reasons should be excluded (including autoimmune diseases, alcoholic or drug-related); (4) unsuited community women in pregnancy and lactation; (5) malignant tumors were excluded; (6) patients with other severe systematic diseases and mental diseases were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| liver function;HBVDNA; | — |
Countries
China
Contacts
Public ContactWang Huifen
Outcome results
None listed